Warren D. Kruger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Warren D. Kruger has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
Sapna Gupta
Fox Chase Cancer Center
38 shared publications- Kathy Q. Cai
Fox Chase Cancer Center 1 Philadelphia, PA
31 shared publications Dustin Rollins
18 shared publications- Débora Barbosa Vendramini Costa
Henry Ford Health System 12 Detroit, Michigan
18 shared publications - Edna Cukierman
Fox Chase Cancer Center
18 shared publications Harvey H. Hensley
18 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 1. Effect of XO and Febuxostat (FX) on 2FA toxicity at 48 hours in two MTAP deleted pancreatic carcinoma cell lines.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 1. Effect of XO and Febuxostat (FX) on 2FA toxicity at 48 hours in two MTAP deleted pancreatic carcinoma cell lines.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 4. Analysis of MiaPaCa-2 SCID experiment.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 4. Analysis of MiaPaCa-2 SCID experiment.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 3. Weight loss and toxicity of HT1080 SCID mice.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 3. Weight loss and toxicity of HT1080 SCID mice.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Homozygous deletion of the methylthioadenosine phosphorylase (MTAP) gene is a frequent genetic alteration in cancer. The MTAP enzyme, which creates adenine from 5′-methylthioadenosine (MTA), is constitutively expressed in all tissues throughout the body. Previously, we described a novel strategy to specifically target MTAP-deleted cancer cells by combining the antipurine prodrug 2-fluoroadenine (2FA) with MTA. In vitro, this combination efficiently kills MTAP− cancer cells while leaving MTAP+ cells unharmed. However, in vivo, the combination was less effective at tumor cell killing, resulting in slower growth but not tumor regression. In this study, we show that this effectiveness difference is associated with a large difference in the amount of 2FA that is incorporated into 2FA-containing nucleotides. To explain this observation, we tested the hypothesis that 2FA was a target for the purine metabolic enzyme xanthine oxidase (XO), which is found in various extracellular fluids. In vitro, the addition of XO protein to culture media effectively abolishes killing by 2FA, and this effect can be fully reversed by the addition of febuxostat (FX), a XO inhibitor. In vivo, the addition of FX to 2FA results in increased cell killing and toxicity, and a 1,000% increase in the amount of 2FA that is converted to its active form, 2FA-monophosphate. Xenograft studies using MTAP− HT1080 and MiaPaCa-2 cell lines show that a 2FA/MTA/FX cocktail can cause tumor regression in vivo. These studies suggest that a combination of 2FA/MTA/FX may be useful in treating MTAP− cancer. Significance:Deletion of the MTAP gene is one of the most frequent genetic alterations in cancer, making it a potentially good target for cancer therapy. Previously, we demonstrated that a combination of 2FA and MTA could specifically target MTAP− cells. In this study, we show that the addition of FX substantially increases the potency of 2FA/MTA in vivo.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Homozygous deletion of the methylthioadenosine phosphorylase (MTAP) gene is a frequent genetic alteration in cancer. The MTAP enzyme, which creates adenine from 5′-methylthioadenosine (MTA), is constitutively expressed in all tissues throughout the body. Previously, we described a novel strategy to specifically target MTAP-deleted cancer cells by combining the antipurine prodrug 2-fluoroadenine (2FA) with MTA. In vitro, this combination efficiently kills MTAP− cancer cells while leaving MTAP+ cells unharmed. However, in vivo, the combination was less effective at tumor cell killing, resulting in slower growth but not tumor regression. In this study, we show that this effectiveness difference is associated with a large difference in the amount of 2FA that is incorporated into 2FA-containing nucleotides. To explain this observation, we tested the hypothesis that 2FA was a target for the purine metabolic enzyme xanthine oxidase (XO), which is found in various extracellular fluids. In vitro, the addition of XO protein to culture media effectively abolishes killing by 2FA, and this effect can be fully reversed by the addition of febuxostat (FX), a XO inhibitor. In vivo, the addition of FX to 2FA results in increased cell killing and toxicity, and a 1,000% increase in the amount of 2FA that is converted to its active form, 2FA-monophosphate. Xenograft studies using MTAP− HT1080 and MiaPaCa-2 cell lines show that a 2FA/MTA/FX cocktail can cause tumor regression in vivo. These studies suggest that a combination of 2FA/MTA/FX may be useful in treating MTAP− cancer. Significance:Deletion of the MTAP gene is one of the most frequent genetic alterations in cancer, making it a potentially good target for cancer therapy. Previously, we demonstrated that a combination of 2FA and MTA could specifically target MTAP− cells. In this study, we show that the addition of FX substantially increases the potency of 2FA/MTA in vivo.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplementary Video 1 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplementary Video 1 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Growth of HT1080 cells in SCID mice. A, Average tumor volume in vehicle (no 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), low-dose treatment (10 mg/kg 2FA, 90 mg/kg MTA, 3.75 mg/kg FX), and high-dose treatment (20 mg/kg 2FA, 180 mg/kg MTA). Arrows show the days when the drug was administered. n = 4 per group. Note: One vehicle-treated mouse was found dead on the day before the end of the study. B, Representative images of tumors stained for Ki-67, myeloperoxidase, and caspase 3. C, Quantitation of staining. Six to eight fields were quantitated for each sample.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Growth of HT1080 cells in SCID mice. A, Average tumor volume in vehicle (no 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), low-dose treatment (10 mg/kg 2FA, 90 mg/kg MTA, 3.75 mg/kg FX), and high-dose treatment (20 mg/kg 2FA, 180 mg/kg MTA). Arrows show the days when the drug was administered. n = 4 per group. Note: One vehicle-treated mouse was found dead on the day before the end of the study. B, Representative images of tumors stained for Ki-67, myeloperoxidase, and caspase 3. C, Quantitation of staining. Six to eight fields were quantitated for each sample.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 2. Effect of FX on cell growth after 48 hours.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Supplemental Figure 2. Effect of FX on cell growth after 48 hours.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Growth of MiaPaCa-2 cells in mice. A, Tumor growth in SCID mice treated with either a high 2FA mix (20 mg/kg 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), a low 2FA mix (10 mg/kg 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), or vehicle (180 mg/kg MTA, 3.75 mg/kg FX). Arrows show the time of treatment. After the initial dose, concentrations of 2FA were halved for both the high- and low-dose groups. B, Tumor growth in nude mice treated with either a low 2FA/MTA ratio (20 mg/kg 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), a high 2FA/MTA ratio (20 mg/kg 2FA, 360 mg/kg MTA, 3.75 mg/kg FX), or vehicle (180 mg/kg MTA, 3.75 mg/kg FX). Again, 2FA concentrations were halved after the first dose. C, Waterfall plot for all xenografts combined.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Growth of MiaPaCa-2 cells in mice. A, Tumor growth in SCID mice treated with either a high 2FA mix (20 mg/kg 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), a low 2FA mix (10 mg/kg 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), or vehicle (180 mg/kg MTA, 3.75 mg/kg FX). Arrows show the time of treatment. After the initial dose, concentrations of 2FA were halved for both the high- and low-dose groups. B, Tumor growth in nude mice treated with either a low 2FA/MTA ratio (20 mg/kg 2FA, 180 mg/kg MTA, 3.75 mg/kg FX), a high 2FA/MTA ratio (20 mg/kg 2FA, 360 mg/kg MTA, 3.75 mg/kg FX), or vehicle (180 mg/kg MTA, 3.75 mg/kg FX). Again, 2FA concentrations were halved after the first dose. C, Waterfall plot for all xenografts combined.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Tissue 2FAMP concentrations. A, Concentration of AMP and 2FAMP in pancreas tissue from mice given 2FA (30 mg/kg), 2FA + FX (3.75 mg/kg), 2FA + FX + MTA (180 mg/kg), or nothing (NT). Mice were treated once per day for 2 days, and tissue was harvested on day 3. n = 3 per group; error bars show SEM. B, 2FAMP/AMP ratio for each group. C, Concentration of AMP and 2FAMP in liver. D, Ratio in liver. Different letters next to points indicate significant differences.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
Tissue 2FAMP concentrations. A, Concentration of AMP and 2FAMP in pancreas tissue from mice given 2FA (30 mg/kg), 2FA + FX (3.75 mg/kg), 2FA + FX + MTA (180 mg/kg), or nothing (NT). Mice were treated once per day for 2 days, and tissue was harvested on day 3. n = 3 per group; error bars show SEM. B, 2FAMP/AMP ratio for each group. C, Concentration of AMP and 2FAMP in liver. D, Ratio in liver. Different letters next to points indicate significant differences.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
FX increases 2FA tissue toxicity in mice. Male 15-week-old C57BL6 mice were given orally either 40 mg/kg 2FA alone, 5 mg/kg FX alone, or both (n = 4). Up arrows indicate treatment days. A, Percent body weight change in mice treated with the indicated drugs. Different letters next to points indicate significant differences. B, Representative images of the spleen, bone marrow, and small intestine of different groups (160× magnification).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5′-Methylthioadenosine in MTAP-Deleted Cancer
FX increases 2FA tissue toxicity in mice. Male 15-week-old C57BL6 mice were given orally either 40 mg/kg 2FA alone, 5 mg/kg FX alone, or both (n = 4). Up arrows indicate treatment days. A, Percent body weight change in mice treated with the indicated drugs. Different letters next to points indicate significant differences. B, Representative images of the spleen, bone marrow, and small intestine of different groups (160× magnification).